Glenmark Pharmaceuticals launches Latanoprost Ophthalmic Solution in the US - Express Pharma

Express Pharma

Factuality

Ownership

Glenmark Pharmaceuticals launches Latanoprost Ophthalmic Solution in the US - Express Pharma

Glenmark Pharmaceuticals Inc., USA (Glenmark) has announced the launch of Latanoprost Ophthalmic Solution, 0.005 per cent (0.05 mg/mL) in the United States. The product is bioequivalent and therapeutically equivalent to the reference listed drug, Xalatan Ophthalmic Solution, 0.005 per cent, of Upjohn US 2 LLC. According to IQVIA sales data for the 12-month period ending December 2024, the market for Xalatan Ophthalmic Solution, 0.005 per cent re…